An Open-label Clinical Trial of Ex Vivo Beta-globin Lentiviral Vector Transduction of Autologous CD34+HSCs (Vebeglogene Autotemcel) for the Treatment of Beta-thalassemia Patients
This is an interventional study to evaluate the safety and efficacy of autologous Hematopoietic Stem Cells (HSCs) transduced with lentiviral vector encoding functional hemoglobin subunit beta (HBB) gene in patients with transfusion-dependent beta-thalassemia.
Study of AAV-hSMN1 (Vesemnogene Lantuparvovec) Gene Therapy in Subjects With Progressive Spinal Muscular Atrophy
This is an interventional study to evaluate safety and efficacy of AAV-hSMN1 in spinal muscular atrophy patients.
100 Clinical Results associated with Lantu Biopharma Inc.
0 Patents (Medical) associated with Lantu Biopharma Inc.
100 Deals associated with Lantu Biopharma Inc.
100 Translational Medicine associated with Lantu Biopharma Inc.